Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Urticaria Facticia Treatment With Omalizumab (UFO) (UFO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02169115
Recruitment Status : Completed
First Posted : June 20, 2014
Results First Posted : January 18, 2016
Last Update Posted : December 20, 2016
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Martin Metz, Charite University, Berlin, Germany

Brief Summary:

Urticaria is a very frequent skin condition characterized by transient wheal and flare type skin reactions associated with severe pruritus. In Europe alone, more than 5 million patients are thought to suffer from persisting urticaria symptoms, which either occur spontaneously, i.e. in chronic spontaneous urticaria (CSU), or as a result of environmental physical stimuli such as friction, pressure, UV irradiation or cold (physical urticaria). Urticaria factitia (also known as dermographic urticaria and symptomatic dermographism) is characterized by whealing and itching following a minor stroking pressure, rubbing or scratching of the skin. The majority of patients with urticaria factitia benefits from treatment with nonsedating antihistamines. Some patients, however, do not achieve adequate symptom control even with updosing of antihistamines and may suffer from substantial quality of life impairment . Since even very minor stroking of the skin can lead to the development of wheals and severe itching, these patients are for example limited in their choice of clothing and are impaired in their social interaction and partnership.

In all patients with a history of wheals after stroking of the skin, a provocation test should be performed. This can be done by stroking of the skin lightly with a smooth blunt object (e.g. the tip of a closed ball point pen or a wooden spatula) or a purpose-built instrument, known as a dermographometer. For the diagnosis of symptomatic dermographism, the smooth blunt object should be held perpendicular to the skin and should be used to apply a light stroking pressure to the skin of the upper back or volar forearm. The reaction is considered positive in patients who show a weal response and report pruritus at the site of provocation.

Patients with a positive test reaction should be evaluated for individual pressure thresholds. For this purpose a provocation device (FricTest) has been developed that allows for reproducible and standardized threshold testing. Threshold testing enables physicians to assess disease severity and treatment response more precisely.

Condition or disease Intervention/treatment Phase
Symptomatic Dermographism Drug: Omalizumab Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind, Placebo-controlled 12-week, Parallel-group Study With a 6 Weeks Follow up Period to Demonstrate Efficacy and Safety of Subcutaneous Omalizumab in Patients With Urticaria Factitia Refractory to Standard Treatment
Study Start Date : December 2012
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hives
Drug Information available for: Omalizumab

Arm Intervention/treatment
Experimental: Omalizumab 150mg Drug: Omalizumab
150mg, s.c., every 4 weeks
Other Name: Xolair

Experimental: Omalizumab 300mg Drug: Omalizumab
300mg, s.c., every 4 weeks
Other Name: Xolair

Placebo Comparator: Placebo Drug: Placebo
Placebo, s.c., every 4 weeks

Primary Outcome Measures :
  1. Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo [ Time Frame: 70 days ]
    Patients receive provocation test by FricTest (standardized stroking of the skin). FricTest ratings are from 0 (no wheal development to the longest pin) to 4 (wheal development to all four pins). The development of wheals within 30 minutes after provocation is monitored.

Secondary Outcome Measures :
  1. To Assess the Effects of Omalizumab in Urticaria Factitia Patients on Quality of Life [ Time Frame: 70 days ]
    Change in quality of life scores assessed by Dermatology Life Quality Index (DLQI) and UF specific life quality questions from baseline to day 70 after treatment with omalizumab compared to placebo.

  2. To Assess the Effects of Omalizumab in UF Patients on Number of Symptom Free Days [ Time Frame: 70 days ]
    Change in number of symptom free days as assessed by a patient diary from baseline to day 70 after treatment with omalizumab compared to placebo

  3. To Assess the Effects of Omalizumab in UF Patients on Physician Global Assessment of Disease Severity [ Time Frame: 70 days ]
    Change in physician global assessment of disease severity assessed by visual analogue scale by a physician from baseline to day 70 after treatment with omalizumab compared to placebo.

  4. To Assess the Effects of Omalizumab in UF Patients on Patient Global Assessment of Disease Severity [ Time Frame: 70 days ]
    Change in patient global assessment of disease severity assessed by visual analogue scale by the patient from baseline to day 70 after treatment with omalizumab compared to placebo.

  5. To Assess Long-term Effects of Omalizumab in UF Patients [ Time Frame: 112 days ]
    To assess long-term effects of omalizumab in UF patients, change in friction thresholds from day 70 (week 10) to day 112 (week 16) will be assessed

  6. To Assess the Safety of Omalizumab in UF Patients [ Time Frame: 112 days ]
    Safety of patients treated with omalizumab: This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults (18-75 years)
  • Informed consent signed and dated
  • Able to read, understand and willing to sign the informed consent form and abide with study procedures
  • Diagnosis of UF lasting for at least 6 months
  • Willing, committed and able to return for all clinic visits and complete all study-related procedures, including willingness to have SC injections administered by a qualified person
  • In females of childbearing potential: Negative pregnancy test; females willing to use highly effective contraception (Pearl-Index < 1). A woman will be considered not of childbearing potential if she is post-menopausal for greater than two years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)
  • No participation in other clinical trials 4 weeks before and after participation in this study

Exclusion Criteria:

  • Patients with acute urticaria
  • Concurrent/ongoing treatment with immunosuppressives (e.g. systemic steroids, cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half lives prior to day 0, whichever is longer
  • Significant medical condition rendering the patient immunocompromised or not suitable for a clinical trial
  • Significant concomitant illness that would adversely affect the subject's participation or evaluation in this study
  • History of malignancies within five years prior to screening other than a successfully treated non-metastatic cutaneous, basal, or squamous cell carcinoma and/or in situ cancer
  • Presence of clinically significant laboratory abnormalities
  • Lactating females or pregnant females
  • Subjects for whom there is concern about compliance with the protocol procedures
  • Any medical condition which, in the opinion of the Investigator, would interfere with participation in the study or place the subject at risk
  • History of substance abuse (drug or alcohol) or any other factor (e.g., serious psychiatric condition) within the last 5 years that could limit the subject's ability to comply with study procedures
  • Subjects who are detained officially or legally to an official institute
  • Previous use of omalizumab within the last 6 months
  • Intake of antihistamines or leukotriene antagonists within 4 days prior to visit 1
  • Intake of oral corticosteroids within 14 days prior to visit 1
  • Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the study
  • Known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study medication or drugs related to omalizumab (e.g.: monoclonal antibodies, polyclonal gammaglobulin)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02169115

Layout table for location information
University Dermatology Freiburg
Freiburg, Germany, 79104
Dermatology University Mainz
Mainz, Germany, 55131
Sponsors and Collaborators
Charite University, Berlin, Germany
Novartis Pharmaceuticals
Layout table for investigator information
Principal Investigator: Martin Metz, MD Charité University

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Martin Metz, Professor, Charite University, Berlin, Germany Identifier: NCT02169115    
Other Study ID Numbers: CIGE025EDE17T
2011-005615-87 ( EudraCT Number )
First Posted: June 20, 2014    Key Record Dates
Results First Posted: January 18, 2016
Last Update Posted: December 20, 2016
Last Verified: November 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Antibodies, Monoclonal
Anti-Allergic Agents
Anti-Asthmatic Agents
Respiratory System Agents
Immunologic Factors
Physiological Effects of Drugs